PDUFA's 'Real-World' Journey Expected To Be Slow Walk
Manufacturers are enthusiastic about the possibility of using real-world evidence to expand product indications. But even with new resource support, they know it's a long road to get there.
You may also be interested in...
In interview with the Pink Sheet, Center for Drug Evaluation and Research director discusses her 30-year career, retirement speculation, and upcoming projects.
PDUFA reauthorization agreement sets up fiscal 2020 as milestone for weaving active surveillance into drug review – and for keeping sponsors informed of activities that affect their products.
Meta-analysis published in JAMA suggests registry-based studies could be alternative to large cardiovascular outcomes trials.